From Yahoo Finance: 2025-05-24 11:02:00

Gilead Sciences, Inc. (NASDAQ:GILD) reports positive results from ASCENT-03 trial, showing Trodelvy’s efficacy in treating metastatic triple-negative breast cancer. Significant progress in first-line mTNBC patients who can’t receive immunotherapy. Stock price rises by 6%. Trodelvy could become foundational treatment for all mTNBC patients. Full data to be shared at ASCO conference.

Investors optimistic about Gilead Sciences, Inc. (NASDAQ:GILD)’s growth prospects in oncology. Stock price rises by 6% following positive results from ASCENT-03 trial. Trodelvy shows meaningful improvement in progression-free survival for first-line mTNBC patients. Company dedicated to improving outcomes for breast cancer patients worldwide. Full data to be presented at ASCO conference.

Gilead Sciences, Inc. (NASDAQ:GILD) stock price rises by 6% after positive results from ASCENT-03 trial. Trodelvy shows promise as foundational treatment for all first-line mTNBC patients. Company’s influence in oncology growing. Full data to be shared at upcoming ASCO conference. Investors optimistic about Gilead’s innovative oncology therapies.



Read more at Yahoo Finance: Gilead Sciences, Inc. (GILD)’s Breast Cancer Study Success Drives Investor Optimism Amid Broader Market Slump